โ† All deals

Tremont AI, Inc.

Other TechnologyAIBiomedicalPreclinical Safety
๐Ÿ“ Boston, MA, United States
StreetZero Signal 64
Be the first to signal interest

About Tremont AI, Inc.

Tremont AI is a Boston-based biomedical AI company building foundation models and agentic AI for preclinical toxicologic pathology. Spun out of the Mahmood Lab at Mass General Brigham, the company develops multimodal foundation models and integrated solutions that help pharmaceutical companies and contract research organizations make preclinical drug safety assessment faster, more consistent, and more computable. The company emerged from stealth with TRACE, ToxScribe, and Tremont Studio tools focused on pathology images, vision-language models, and evidence integration. It announced a research collaboration with AstraZeneca to develop AI solutions for accelerated preclinical safety assessment.

LATEST FUNDINGPrivate Placement
$2.0M
Announced 2026-11-04
TOTAL RAISED$2M
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Tremont AI, Inc..

Free plan includes 3 full deal profiles every month.

Investors

Not disclosed in the source filing. Form D filings do not list investors โ€” StreetZero surfaces them from news where available.

Key highlights

  • Emerged from stealth with multimodal AI platform for preclinical drug safety.
  • Spun out of Mahmood Lab at Mass General Brigham with exclusively licensed technology.
  • Announced research collaboration with AstraZeneca for AI in preclinical safety assessment.
  • Developing TRACE, ToxScribe, and Tremont Studio tools for pathology image analysis and interpretation.
  • Targeting pharma and CRO teams with early-access evaluated partnerships.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account